DE40: Cautious optimism on European markets

The first half of the session in European markets is characterized by cautious optimism among investors. The positive sentiment is fueled by the extension of the trade truce between the USA and China. This may support luxury companies in the long term, although today's session does not yet indicate this. Uncertainty persists due to upcoming peace negotiations in Alaska and unsatisfactory macroeconomic prospects for some European countries. DE40 and EU50 are losing 0.15% and 0.05% respectively before noon, while other European indices are recording gains around 0.2-0.4%.

Investor attention is focused on key macroeconomic data from the USA, which could determine the further direction of the European session. Volatility is currently observed in selected contracts based on European indices

Source: xStation

Technical Analysis - DE40

DE40 continues yesterday's declines, currently hovering around the previous day's session lows of approximately 24,080 points. On the chart, we can clearly see a forming narrowing triangle pattern, after which the market will likely set the direction for the coming days. The next technical support is at 23,983 points where the EMA-50 is located, followed by the upward trend line starting in April this year and the EMA-100. If these are breached, further declines can be expected. However, optimism on the chart is added by long and medium-term upward trend lines.

Company Information:

Sartorius (SRT.DE) - The company is seeing gains of over 3.5% after receiving a "Buy" recommendation from Jefferies, with a price target of 263 euros. This implies a predicted price increase of over 50% by analysts.

Spirax Group (SPX.UK) - The company's shares are up 16% after publishing reports boasting a growing order portfolio.

Hannover Re (HNR.DE) - The company reported an increase in net revenue in the first half of 2025, but the EBIT result was noticeably below expectations. Optimistic assurances from the company regarding further revenue growth did not convince investors, resulting in a 3% drop in shares.

K+S (SDF.DE) - The published EBITDA result missed investor expectations, falling 14% year-on-year. The share price continues the downward trend of recent weeks.

Valneva (VALN.US) - The French biotechnology company reports a 37% increase in revenue, translating to a 1.5% rise in share price. This is mainly due to strong sales of their IXiaro and Jaspect vaccines.